Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligibility Criteria:
Active rheumatoid arthritis currently failing anti-TNF therapy or have failed anti-TNF therapy in the past.
You may not be if
Women who are pregnant or breast feeding
Current symptoms of serious medical disease
History of cancer in last 5 years other than non-melanoma skin cancer
Chronic serious infection
Active TB requiring treatment in last 5 years
Herpes zoster in last 2 months
Any active viral infection including Human Immunodeficiency Virus (HIV)
Serious side effects associated with previous anti-TNF therapy
Clareo Health | Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
